Earnings call transcript: Inspire Medical beats Q3 2026 estimates, shares rise after hours

Inspire Medical Systems reported Q3 2026 adjusted EPS of $0.14 versus $0.09 expected and revenue of $206.7 million versus a $204.31 million forecast, although revenue declined 7.9% year over year. Coding and reimbursement challenges reduced Q3 results by about $30 million; management estimates an approximately $120 million impact for 2026 and narrowed full-year revenue guidance to $850 million–$860 million. The company expects low-single-digit revenue growth in 2027, while shares rose 1.83% after hours to $68.44.

Analysis

The key underwriting question is conversion, not whether reimbursement disruption has peaked: management’s 2027 low-single-digit growth outlook suggests only a cautious recovery despite easier comparisons, new commercial investment, and possible recapture of deferred patients. The stated 2026 coding/reimbursement impact should not be treated as a revenue backlog; some patients may leave the funnel, and the company has not quantified the recoverable portion. That makes patient flow and procedure volumes more informative than adjusted EPS beats, which appear more sensitive to mix and expense control than demand acceleration.

Near term, the final 2027 OPPS rule is the binary catalyst. A favorable facility rate could improve site economics and support ASC adoption; a less favorable outcome, or a weak physician-fee valuation through the RUC process, would undermine the recovery narrative even if coding becomes simpler. The 2028 Category I code is a longer-dated administrative simplification, not proof of higher reimbursement. ASC migration and added field support could expand access, but execution must show up in center utilization rather than staffing and marketing spend alone.

Contrarian read: the modest growth guide may leave upside if deferred patients return and commercial initiatives work, but investors may be underestimating the risk that “stabilization” is mistaken for normalization. International recovery is also not a dependable offset until Germany destocking reverses. The balance sheet reduces financing risk, not commercial or reimbursement risk.

Key Decisions for Investors

• Avoid chasing the post-release move. Treat INSP as a catalyst watch through the final OPPS rule expected later this week; verify the actual facility rates and effective dates rather than relying on management’s characterization of the proposal.
• If the final rule is supportive, consider a staged INSP long or a 3–6 month call spread after the event, sized as a recovery trade rather than a return-to-prior-growth bet. Require subsequent evidence in U.S. procedures, ASC utilization, and patient conversion; options pricing and liquidity should be checked before implementation.
• If rates disappoint or 2027 growth assumptions are cut, avoid adding and consider reducing exposure; the thesis is falsified by weaker procedure trends, a lower revenue outlook, or RUC valuation that makes physician economics unattractive.
• Track quarterly patient-flow conversion, center utilization, U.S. territory productivity, and Germany orders. These are the evidence needed to distinguish a temporary coding pause from a durable demand shortfall; do not count the estimated 2026 headwind as automatically recoverable.